Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 7, July, p. 879–886

doi: 10.17219/acem/81935

Publication type: original article

Language: English

License: Creative Commons Attribution Non-Commercial License

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The prognostic value and non-invasive predictors of splenomegaly in cirrhotic patients with hepatocellular carcinoma following curative resection

Li Zhou1,A,B,C,D,E,F, Shao-Bin Wang1,B, Shu-Guang Chen1,B, Qiang Qu1,C, Jing-An Rui1,C,D,E

1 Department of General Surgery, Peking Union Medical College Hospital, Beijing, China


Background. The prognostic value and non-invasive predictors of splenomegaly in cirrhotic patients with hepatocellular carcinoma (HCC) after curative resection remain unknown.
Objectives. To investigate the prognostic value and non-invasive predictors of splenomegaly in cirrhotic patients with HCC after curative resection.
Material and Methods. The medical records of 78 patients with HCC and liver cirrhosis who underwent curative resection were retrospectively reviewed. The influence of spleen size, measured with clinically routine ultrasonography (USG), on overall and disease-free survival was evaluated using univariate and multivariate analyses. The efficiency of some frequently used blood-derived liver function parameters and non-invasive fibrosis markers to predict splenomegaly was also assessed.
Results. It was shown that tumor size >5 cm, the presence of microvascular invasion, tumor-node metastasis (TNM) stage III–IVA of the tumor, spleen size >11.45 cm, and age ≤52 years were associated with poor overall survival and/or disease-free survival in univariate analyses (all p < 0.05). In multivariate analyses, spleen size was identified as an independent predictor for both overall and disease-free survival (p < 0.001 and p = 0.012, respectively). On the other hand, platelet count, aspartate aminotransferase (AST) to platelet ratio index (APRI) and Fibrosis-4 index (FIB-4) scores were significantly different between small and large spleen groups (p = 0.026, 0.003 and 0.003, respectively), while statistical differences for albumin, alanine aminotransferase (ALT), AST, total bilirubin, AST to ALT ratio (AAR), and age-platelet index (API) were not found. Using receiver operating characteristic (ROC) curves, high powers of platelet count, APRI and FIB-4 in splenomegaly prediction were confirmed.
Conclusion. Splenomegaly, which can be predicted by some non-invasive variables, serves as a strong determinant for postresectional prognoses of cirrhotic patients with HCC.

Key words

splenomegaly, prognosis, hepatocellular carcinoma, non-invasive markers

References (25)

  1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127.
  2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
  3. Kluger MD, Salceda JA, Laurent A, et al. Liver resection for hepatocellular carcinoma in 313 Western patients: Tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62(5):1131–1140.
  4. Chen HW, Shan L, Wan-Yee L, et al. Prognostic impact of hepatic resection for hepatocellular carcinoma. The role of the surgeon in achieving R0 resection: A retrospective cohort study. Int J Surg. 2015;13:297–301.
  5. Xu XS, Chen W, Miao RC, et al. Survival analysis of hepatocellular carcinoma: A comparison between young patients and aged patients. Chin Med J (Engl). 2015;128(13):1793–1800.
  6. Goh BK, Teo JY, Chan CY, et al. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system. J Surg Oncol. 2016;113(1):89–93.
  7. Liu W, Wang K, Bao Q, Sun Y, Xing BC. Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma. World J Surg Oncol. 2016;14:62.
  8. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–1916.
  9. Tang YH, Zhu WJ, Wen TF. Influence of clinically significant portal hypertension on hepatectomy for hepatocellular carcinoma: A meta-analysis. Asian Pac J Cancer Prev. 2014;15(4):1649–1654.
  10. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Hepatology. 2015;61(2):526–536.
  11. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250(6):922–928.
  12. Santambrogio R, Kluger MD, Costa M, et al. Hepatic resection for hepatocellular carcinoma in patients with Child–Pugh’s A cirrhosis: Is clinical evidence of portal hypertension a contraindication? HPB (Oxford). 2013;15(1):78–84.
  13. He W, Zeng Q, Zheng Y, et al. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: A propensity score-matching analysis. BMC Cancer. 2015; 15:263.
  14. Cheng CH, Lee CF, Wu TH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114.
  15. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503.
  16. Su CW, Chan CC, Hung HH, et al. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2009;43(9):876–883.
  17. Poynard T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997;4(3):199–208.
  18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.
  19. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4, an inexpensive and accurate marker of fibrosis in HCV infection: Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36.
  20. Wu WC, Chiou YY, Hung HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46(9):789–795.
  21. Xu M, Xie F, Qian G, et al. Peritumoral ductular reaction: A poor postoperative prognostic factor for hepatocellular carcinoma. BMC Cancer. 2014;14:65.
  22. Cai X, Li F, Zhang Q, et al. Peritumoral ductular reaction is related to nuclear translocation of β-catenin in hepatocellular carcinoma. Biomed Pharmacother. 2015;76:11–16.
  23. Iranmanesh P, Vazquez O, Terraz S, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol. 2014;60(5):969–974.
  24. Ishibashi H, Higuchi N, Shimamura R, Hirata Y, Kudo J, Niho Y. Sonographic assessment and grading of spleen size. J Clin Ultrasound. 1991;19(1):21–25.
  25. Eminler AT, Ayyildiz T, Irak K, et al. AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J Gastroenterol Hepatol. 2015;27(12):1361–1366.